Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
Sponsor: University of Pennsylvania
Summary
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD), Alzheimer's Disease (AD) and healthy controls. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WUSTL). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.
Official title: Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 18F-JSS20-183A
Key Details
Gender
All
Age Range
40 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-05-09
Completion Date
2030-04
Last Updated
2025-12-23
Healthy Volunteers
No
Conditions
Interventions
18F-JSS20-183A PET
2 hour Positron Emission Tomography (PET) scan using new radiotracer 18F-JSS20-183A.
Brain MRI
MRI scan of the brain.
Amyloid PET
PET scan with Florbetaben F18 or 11C-PiB.
Neurological Assessments
Neurological assessments, including a video interview.
Locations (2)
University of California
San Francisco, California, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States